Shares of Biomerica, Inc. (NASDAQ:BMRA) have earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.
Analysts have set a 1 year consensus target price of $6.63 for the company and are forecasting that the company will post ($0.08) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Biomerica an industry rank of 90 out of 256 based on the ratings given to its competitors.
Separately, B. Riley set a $6.00 price objective on shares of Biomerica and gave the stock a “buy” rating in a report on Friday, July 19th.
An institutional investor recently bought a new position in Biomerica stock. Heritage Investors Management Corp acquired a new position in shares of Biomerica, Inc. (NASDAQ:BMRA) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 15,550 shares of the company’s stock, valued at approximately $39,000. Heritage Investors Management Corp owned 0.17% of Biomerica at the end of the most recent quarter. Institutional investors and hedge funds own 1.31% of the company’s stock.
Biomerica Company Profile
Biomerica, Inc, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations.
Further Reading: Why are analyst ratings important in trading stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.